Previous 10 | Next 10 |
2023-12-26 08:19:44 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript BrainStorm, FDA to discuss regulatory path forward for ALS therapy Brainstorm realigns resources to support NurOwn development ...
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments PR Newswire NEW YORK , Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for n...
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS PR Newswire Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK , Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a le...
2023-11-20 10:57:50 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS PR Newswire Meeting will take place on December 6 ; Company plans to seek Special Protocol Assessment (SPA) NEW YORK , Nov....
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia PR Newswire Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK , Nov. 17, 2023 /PRNewswire...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...
2023-11-14 12:20:09 ET Start Time: 08:30 End Time: 08:58 BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis -...
2023-11-14 07:07:42 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegener...
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS PR Newswire NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes ...